Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 651935, 4 pages
http://dx.doi.org/10.1155/2014/651935
Research Article

Pfetin as a Risk Factor of Recurrence in Gastrointestinal Stromal Tumors

1Department of Surgery, Juntendo Shizuoka Hospital, Shizuoka, Japan
2Department of Pathology, Juntendo Shizuoka Hospital, Shizuoka, Japan
3Proteome Bioinformatics Project, National Cancer Center Research Institute, Japan

Received 12 December 2013; Revised 15 March 2014; Accepted 29 March 2014; Published 26 May 2014

Academic Editor: Gautam Sethi

Copyright © 2014 Hajime Orita et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Miettinen, M. Sarlomo-Rikala, and J. Lasota, “Gastrointestinal stromal tumours,” Annales Chirurgiae et Gynaecologiae, vol. 87, no. 4, pp. 278–281, 1998. View at Google Scholar · View at Scopus
  2. J. A. Breiner, J. Meis-Kindblom, L.-G. Kindblom et al., “Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors),” Cancer Genetics and Cytogenetics, vol. 120, no. 2, pp. 111–116, 2000. View at Publisher · View at Google Scholar · View at Scopus
  3. H. Yamamoto, Y. Oda, K.-I. Kawaguchi et al., “c-kit and PDGFRA Mutations in Extragastrointestinal Stromal Tumor (Gastrointestinal Stromal Tumor of the Soft Tissue),” The American Journal of Surgical Pathology, vol. 28, no. 4, pp. 479–488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. G. D. Demetri, P. Reichardt, Y. K. Kang et al., “Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial,” The Lancet, vol. 381, no. 9863, pp. 295–302, 2013. View at Google Scholar
  5. T. Nishida, K. Shirao, A. Sawaki et al., “Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202),” International Journal of Clinical Oncology, vol. 13, no. 3, pp. 244–251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Joensuu, C. Fletcher, S. Dimitrijevic et al., “Management of malignant gastrointestinal stromal tumours,” The Lancet Oncology, vol. 3, no. 11, pp. 655–664, 2002. View at Google Scholar
  7. M. Miettinen and J. Lasota, “Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics,” Polish Journal of Pathology, vol. 54, no. 1, pp. 3–24, 2003. View at Google Scholar · View at Scopus
  8. R. P. DeMatteo, K. V. Ballman, C. R. Antonescu et al., “Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial,” The Lancet, vol. 373, no. 9669, pp. 1097–1104, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Rajendra, S. M. Pollack, and R. L. Jones, “Management of gastrointestinal stromal tumors,” Future Oncology, vol. 9, no. 2, pp. 193–206, 2013. View at Google Scholar
  10. M. Miettinen, M. Majidi, and J. Lasota, “Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review,” European Journal of Cancer, vol. 38, supplement 5, pp. S39–S51, 2002. View at Google Scholar · View at Scopus
  11. J. Berman and T. J. O'Leary, “Gastrointestinal stromal tumor workshop,” Human Pathology, vol. 32, no. 6, pp. 578–582, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. K. Pornsuksiri, S. Chewatanakornkul, S. Kanngurn et al., “Clinical outcomes of gastrointestinal stromal tumor in southern Thailand,” World Journal of Gastrointestinal Oncology, vol. 4, no. 11, pp. 216–222, 2012. View at Google Scholar
  13. M. Valadão and E. Linhares, “The role of the surgeon in the management of GIST,” Revista do Colegio Brasileiro de Cirurgioes, vol. 36, no. 3, pp. 261–265, 2009. View at Google Scholar · View at Scopus
  14. D. T. Alexandrescu, C. A. Dasanu, H. Farzanmehr, and C. L. Kauffman, “Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST,” Dermatology Online Journal, vol. 14, no. 7, article 8, 2008. View at Google Scholar · View at Scopus
  15. Y. Suehara, T. Kondo, K. Seki et al., “Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics,” Clinical Cancer Research, vol. 14, no. 6, pp. 1707–1717, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. B. L. Resendes, S. F. Kuo, N. G. Robertson et al., “Isolation from cochlea of a novel human intronless gene with predominant fetal expression,” Journal of the Association for Research in Otolaryngology, vol. 5, no. 2, pp. 185–202, 2004. View at Google Scholar · View at Scopus
  17. C. B. Tan, W. Zhi, G. Shahzad, and P. Mustacchia, “Gastrointestinal stromal tumors: a review of case reports, diagnosis, treatment, and future directions,” ISRN Gastroenterology, vol. 2012, Article ID 595968, 16 pages, 2012. View at Publisher · View at Google Scholar
  18. A. Rammohan, J. Sathyanesan, K. Rajendran et al., “A gist of gastrointestinal stromal tumors: a review,” World Journal of Gastrointestinal Oncology, vol. 5, no. 6, pp. 102–112, 2013. View at Google Scholar
  19. J. S. Gold, M. Gönen, A. Gutiérrez et al., “Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis,” The Lancet Oncology, vol. 10, no. 11, pp. 1045–1052, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Grover, S. W. Ashley, and C. P. Raut, “Small intestine gastrointestinal stromal tumors,” Current Opinion in Gastroenterology, vol. 28, no. 2, pp. 113–123, 2012. View at Publisher · View at Google Scholar · View at Scopus